• Age \> 18

• Histologically confirmed diagnosis of prostate adenocarcinoma

• Metastatic disease documented by ≥1 bone lesion with Technetium 99m (99mTc) bone scan. Individuals with only one bone lesion should have confirmation of that lesion on CT or MRI.

• Eastern Cooperative Oncology Group Performance Status (ECOG PS) Grade ≤ 2

• No previous treatment with antiandrogens or GnRH analogues, or a treatment ≤ 3 months.

• No previous systemic or local treatment for prostate adenocarcinoma, including pelvic radiotherapy.

• Laboratory values at the time of screening:

• a. Neutrophils ≥ 1500/μL b. Hemoglobin ≥ 9.0 mg/μL (no transfusions in the past 28 days) c. Platelets ≥ 100,000/μL d. Creatinine ≤ 2 x upper limit of normal and serum albumin ≥ 3.0 g/dL f. Total bilirubin ≤ 1.5 x upper limit of normal \[NOTE: In subjects with Gilbert syndrome, if total bilirubin is \>1.5 x ULN, measure direct and indirect bilirubin, and if direct bilirubin is ≤ 1.5 x ULN subjects may be eligible\]; g. AST and ALT ≤ 2.5 x upper limit of normal

• Able to swallow Apalutamide tablets whole.

• All subjects must sign an Informed Consent Form indicating that they understand the purpose of the study and its procedures and intend to participate. The subject must be willing and must be able to comply with the restrictions specified in this protocol.

• Age \>18 years

• Clinical stage cT3

• Robot-assisted radical prostatectomy with iliac obturator lymphadenectomy

• Surgical piece management criteria similar to Proteus criteria.